<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00264251</url>
  </required_header>
  <id_info>
    <org_study_id>SLRHC 02-117</org_study_id>
    <nct_id>NCT00264251</nct_id>
  </id_info>
  <brief_title>Diet, Exercise and/or Rosiglitazone for HIV-Associated Insulin Resistance</brief_title>
  <official_title>Effect of Diet, Exercise and Rosiglitazone on Regional Fat and Insulin Resistance in HIV-Infected and Uninfected Men and Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Luke's-Roosevelt Hospital Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Luke's-Roosevelt Hospital Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if, in men and women with excess abdominal fat and&#xD;
      insulin resistance, people with HIV infection respond differently than people without HIV to&#xD;
      interventions that typically improve body fat distribution and insulin resistance. The&#xD;
      specific interventions are:&#xD;
&#xD;
        1. Diet + exercise program.&#xD;
&#xD;
        2. Rosiglitazone treatment.&#xD;
&#xD;
        3. A combination treatment of diet + exercise program and rosiglitazone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A constellation of nutritional alterations in HIV-infected patients receiving highly active&#xD;
      antiretroviral therapies (HAART), including body fat redistribution with subcutaneous adipose&#xD;
      tissue (SAT) wasting and visceral adipose tissue (VAT) accumulation, hyperlipidemia, and&#xD;
      insulin resistance (IR) has been described. There is a major concern that these developments&#xD;
      will be associated with adverse clinical outcomes related to atherosclerosis, as suggested by&#xD;
      several case reports (Henry 1998, Behrens 1998, Gallet 1998, Vittecoq 1998). Although there&#xD;
      are well documented associations among body fat distribution, insulin resistance, and adverse&#xD;
      health outcomes, especially accelerated atherosclerosis, in non-HIV infected individuals, it&#xD;
      is unclear if the relationships are affected by HIV infection, or if they reflect the same&#xD;
      outcomes. This information is important, since understanding the interrelationships between&#xD;
      body fat distribution and metabolism may guide the development of treatment strategies.&#xD;
&#xD;
      The specific hypotheses to be tested are:&#xD;
&#xD;
        1. HIV infection does not affect the relative reductions in visceral (VAT) and subcutaneous&#xD;
           adipose tissue (SAT) resulting from diet + exercise, but decreases the effect of this&#xD;
           therapy on insulin resistance.&#xD;
&#xD;
        2. HIV infection decreases the changes in insulin resistance and body composition (increase&#xD;
           in SAT and decrease in VAT) expected with rosiglitazone.&#xD;
&#xD;
        3. The combination treatment of diet+exercise and rosiglitazone will reduce VAT to a&#xD;
           greater extent than rosiglitazone alone, and will improve insulin resistance to greater&#xD;
           extent than diet and exercise alone, however these effects will be blunted in&#xD;
           HIV-infected subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin sensitivity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Body composition</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Strength and fitness</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid profile</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional cardiovascular risk indicators</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">48</enrollment>
  <condition>HIV Infections</condition>
  <condition>Insulin Resistance</condition>
  <condition>Obesity</condition>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Weight loss through diet and exercise</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosiglitazone insulin sensitizing agent</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV-infected or uninfected.&#xD;
&#xD;
          -  Body mass index (BMI) at least 25.&#xD;
&#xD;
          -  Excess visceral adipose tissue. Excess VAT will be determined in HIV+ and HIV- groups&#xD;
             of men by a waist hip ratio &gt; 0.95 and a waist circumference &gt;88.2 cm, and in women by&#xD;
             a waist:hip &gt;0.9 and waist circumference &gt;75.3 cm.&#xD;
&#xD;
          -  Insulin resistance (fasting serum insulin level &gt;16 Î¼U/ml).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to tolerate magnetic resonance imaging (MRI)&#xD;
&#xD;
          -  Clinical evidence of active liver disease or a significantly abnormal liver function&#xD;
             test (ALT &gt;2.5x the upper limit of normal).&#xD;
&#xD;
          -  Severe hyperlipidemia (fasting plasma triglycerides &gt;500 mg/dL or fasting total&#xD;
             cholesterol &gt;300mg/dL)&#xD;
&#xD;
          -  Current coronary artery disease including angina&#xD;
&#xD;
          -  Peripheral vascular disease&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Participation in a regular exercise program&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald P Kotler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Luke's-Roosevelt Hospital Center, Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeanine B Albu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Luke's-Roosevelt Hospital Center, Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Luke's-Roosevelt Hospital Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2007</verification_date>
  <study_first_submitted>December 9, 2005</study_first_submitted>
  <study_first_submitted_qc>December 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2005</study_first_posted>
  <last_update_submitted>October 26, 2007</last_update_submitted>
  <last_update_submitted_qc>October 26, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2007</last_update_posted>
  <keyword>HIV</keyword>
  <keyword>Body composition</keyword>
  <keyword>Weight reduction</keyword>
  <keyword>Insulin resistance/sensitivity</keyword>
  <keyword>Exercise</keyword>
  <keyword>Diet</keyword>
  <keyword>Visceral adiposity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosiglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

